edoc

Detection of Sp110 by Flow Cytometry and Application to Screening Patients for Veno-occlusive Disease with Immunodeficiency

Marquardsen, Florian A. and Baldin, Fabian and Wunderer, Florian and Al-Herz, Waleed and Mikhael, Raymond and Lefranc, Gérard and Baz, Zeina and Rezaee, Fariba and Hanna, Rabi and Kfir-Erenfeld, Shlomit and Stepensky, Polina and Meyer, Benedikt and Jauch, Annaise and Bigler, Marc B. and Burgener, Anne-Valérie and Higgins, Rebecca and Navarini, Alexander A. and Church, Joeseph A. and Chou, Janet and Geha, Raif and Notarangelo, Luigi D. and Hess, Christoph and Berger, Christoph T. and Bloch, Donald B. and Recher, Mike. (2017) Detection of Sp110 by Flow Cytometry and Application to Screening Patients for Veno-occlusive Disease with Immunodeficiency. Journal of clinical immunology, 37 (7). pp. 707-714.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/62091/

Downloads: Statistics Overview

Abstract

Mutations in Sp110 are the underlying cause of veno-occlusive disease with immunodeficiency (VODI), a combined immunodeficiency that is difficult to treat and often fatal. Because early treatment is critically important for patients with VODI, broadly usable diagnostic tools are needed to detect Sp110 protein deficiency. Several factors make establishing the diagnosis of VODI challenging: (1) Current screening strategies to identify severe combined immunodeficiency are based on measuring T cell receptor excision circles (TREC). This approach will fail to identify VODI patients because the disease is not associated with severe T cell lymphopenia at birth; (2) the SP110 gene contains 17 exons, making it a challenge for Sanger sequencing. The recently developed next-generation sequencing (NGS) platforms that can rapidly determine the sequence of all 17 exons are available in only a few laboratories; (3) there is no standard functional assay to test for the effects of novel mutations in Sp110; and (4) it has been difficult to use flow cytometry to identify patients who lack Sp110 because of the low level of Sp110 protein in peripheral blood lymphocytes. We report here a novel flow cytometric assay that is easily performed in diagnostic laboratories and might thus become a standard assay for the evaluation of patients who may have VODI. In addition, the assay will facilitate investigations directed at understanding the function of Sp110.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Immunodeficiency (Recher)
03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Translational Immunology (Berger)
UniBasel Contributors:Berger, Christoph T. and Recher, Mike
Item Type:Article, refereed
Article Subtype:Research Article
ISSN:0271-9142
e-ISSN:1573-2592
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:13 Jul 2019 10:18
Deposited On:13 Jul 2019 10:18

Repository Staff Only: item control page